spacer
home > > autumn 2008 > intellectual property
PUBLICATIONS


Intellectual Property

The continued growth and prosperity of the pharmaceutical industry relies on the exploitation of existing products and innovation. The industry faces, in particular, difficulties of competition (both lawful and unlawful), heavy regulation, consumer interest and public policy. It is vital for a pharmaceutical company to develop a strategy that protects its position in the industry, allows it to expand, maximises its investment and continues innovation whilst dealing with the competitive regulated market. Intellectual property (IP) rights are critical tools which assist pharmaceutical companies in crossing this minefield.

THE NEED FOR AN IP STRATEGY

In an industry where the cost of research and development equates to 33.3 per cent of the revenue from sales, it is crucial for businesses to protect the investment incurred in carrying out that R&D (1). IP can be a pharmaceutical company’s most valuable resource. Mismanagement and failure to protect IP can lead to serious damage to the value of a business. The right IP strategy can maximise the return on the investment and assist with sustainability and commercialisation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Bell is a Lawyer in the Commercial and Intellectual Property department at Brabners Chaffe Street LLP, Solicitors, based in their Liverpool office. Colin has extensive experience in all aspects of contentious and non-contentious IP and advises on the identification, protection, exploitation and enforcement of IP, which includes filing and prosecuting trade mark and design applications. He is also part of the biotechnology multidisciplinary team at Brabners Chaffe Street LLP.
spacer
Colin Bell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Smart Bioprocessing with the new Eppendorf Control System

Hamburg, February 12, 2020 Working with flexible systems that evolve with the changing needs in a lab is indispensable. With the SciVario twin, Eppendorf, a key life science company, introduces its latest bioreactor control system for small- and bench-scale applications. The intelligent controller and new, innovative bay-drawer system enables the exchange of standardized modules to flexibly adapt the controller to the changing requirements in a laboratory.
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement